Dolaflexin, DolaLock, Publications, UpRi (XMT-1536) Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b June 2019